vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Perimeter Solutions, Inc. (PRM). Click either name above to swap in a different company.

Perimeter Solutions, Inc. is the larger business by last-quarter revenue ($102.8M vs $74.7M, roughly 1.4× Health Catalyst, Inc.). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -136.5%, a 14.6% gap on every dollar of revenue. On growth, Perimeter Solutions, Inc. posted the faster year-over-year revenue change (19.2% vs -6.2%). Perimeter Solutions, Inc. produced more free cash flow last quarter ($11.6M vs $9.6M). Over the past eight quarters, Perimeter Solutions, Inc.'s revenue compounded faster (31.9% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Perimeter 81 is an Israeli cloud and network security company that develops secure remote networks, based on the zero trust architecture, for organizations. Its technology replaces legacy security appliances like VPNs and firewalls.

HCAT vs PRM — Head-to-Head

Bigger by revenue
PRM
PRM
1.4× larger
PRM
$102.8M
$74.7M
HCAT
Growing faster (revenue YoY)
PRM
PRM
+25.3% gap
PRM
19.2%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
14.6% more per $
HCAT
-121.9%
-136.5%
PRM
More free cash flow
PRM
PRM
$2.0M more FCF
PRM
$11.6M
$9.6M
HCAT
Faster 2-yr revenue CAGR
PRM
PRM
Annualised
PRM
31.9%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
PRM
PRM
Revenue
$74.7M
$102.8M
Net Profit
$-91.0M
$-140.2M
Gross Margin
45.2%
Operating Margin
-115.3%
-160.7%
Net Margin
-121.9%
-136.5%
Revenue YoY
-6.2%
19.2%
Net Profit YoY
-340.3%
-197.3%
EPS (diluted)
$-1.29
$-0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
PRM
PRM
Q4 25
$74.7M
$102.8M
Q3 25
$76.3M
$315.4M
Q2 25
$80.7M
$162.6M
Q1 25
$79.4M
$72.0M
Q4 24
$79.6M
$86.2M
Q3 24
$76.4M
$288.4M
Q2 24
$75.9M
$127.3M
Q1 24
$74.7M
$59.0M
Net Profit
HCAT
HCAT
PRM
PRM
Q4 25
$-91.0M
$-140.2M
Q3 25
$-22.2M
$-90.7M
Q2 25
$-41.0M
$-32.2M
Q1 25
$-23.7M
$56.7M
Q4 24
$-20.7M
$144.2M
Q3 24
$-14.7M
$-89.2M
Q2 24
$-13.5M
$21.6M
Q1 24
$-20.6M
$-82.6M
Gross Margin
HCAT
HCAT
PRM
PRM
Q4 25
45.2%
Q3 25
52.6%
63.1%
Q2 25
62.4%
Q1 25
39.1%
Q4 24
48.6%
Q3 24
47.5%
62.8%
Q2 24
57.6%
Q1 24
35.1%
Operating Margin
HCAT
HCAT
PRM
PRM
Q4 25
-115.3%
-160.7%
Q3 25
-22.9%
-27.7%
Q2 25
-46.0%
-16.1%
Q1 25
-25.4%
Q4 24
-22.0%
71.1%
Q3 24
-17.9%
-12.2%
Q2 24
-20.8%
35.4%
Q1 24
-30.5%
-126.8%
Net Margin
HCAT
HCAT
PRM
PRM
Q4 25
-121.9%
-136.5%
Q3 25
-29.1%
-28.7%
Q2 25
-50.8%
-19.8%
Q1 25
-29.9%
78.7%
Q4 24
-26.0%
167.2%
Q3 24
-19.3%
-30.9%
Q2 24
-17.8%
17.0%
Q1 24
-27.6%
-139.8%
EPS (diluted)
HCAT
HCAT
PRM
PRM
Q4 25
$-1.29
$-0.89
Q3 25
$-0.32
$-0.62
Q2 25
$-0.59
$-0.22
Q1 25
$-0.35
$0.36
Q4 24
$-0.33
$1.00
Q3 24
$-0.24
$-0.61
Q2 24
$-0.23
$0.14
Q1 24
$-0.35
$-0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
PRM
PRM
Cash + ST InvestmentsLiquidity on hand
$95.7M
$325.9M
Total DebtLower is stronger
$153.3M
$669.1M
Stockholders' EquityBook value
$245.8M
$1.1B
Total Assets
$502.6M
$2.7B
Debt / EquityLower = less leverage
0.62×
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
PRM
PRM
Q4 25
$95.7M
$325.9M
Q3 25
$91.5M
$340.6M
Q2 25
$97.3M
$140.7M
Q1 25
$342.0M
$200.1M
Q4 24
$392.0M
$198.5M
Q3 24
$387.3M
$223.1M
Q2 24
$308.3M
$43.2M
Q1 24
$327.8M
$38.7M
Total Debt
HCAT
HCAT
PRM
PRM
Q4 25
$153.3M
$669.1M
Q3 25
$153.1M
$668.8M
Q2 25
$153.0M
$668.4M
Q1 25
$382.9M
$668.1M
Q4 24
$382.4M
$667.8M
Q3 24
$345.0M
$667.4M
Q2 24
$667.1M
Q1 24
$666.8M
Stockholders' Equity
HCAT
HCAT
PRM
PRM
Q4 25
$245.8M
$1.1B
Q3 25
$331.9M
$1.1B
Q2 25
$347.5M
$1.2B
Q1 25
$376.8M
$1.2B
Q4 24
$365.2M
$1.2B
Q3 24
$355.0M
$1.0B
Q2 24
$357.0M
$1.1B
Q1 24
$357.2M
$1.1B
Total Assets
HCAT
HCAT
PRM
PRM
Q4 25
$502.6M
$2.7B
Q3 25
$587.1M
$2.6B
Q2 25
$616.2M
$2.5B
Q1 25
$891.5M
$2.4B
Q4 24
$858.9M
$2.4B
Q3 24
$813.0M
$2.5B
Q2 24
$691.7M
$2.3B
Q1 24
$695.1M
$2.3B
Debt / Equity
HCAT
HCAT
PRM
PRM
Q4 25
0.62×
0.59×
Q3 25
0.46×
0.60×
Q2 25
0.44×
0.57×
Q1 25
1.02×
0.55×
Q4 24
1.05×
0.58×
Q3 24
0.97×
0.67×
Q2 24
0.62×
Q1 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
PRM
PRM
Operating Cash FlowLast quarter
$9.9M
$18.6M
Free Cash FlowOCF − Capex
$9.6M
$11.6M
FCF MarginFCF / Revenue
12.9%
11.3%
Capex IntensityCapex / Revenue
0.4%
6.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$208.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
PRM
PRM
Q4 25
$9.9M
$18.6M
Q3 25
$-464.0K
$198.7M
Q2 25
$-9.0M
$-2.9M
Q1 25
$280.0K
$23.7M
Q4 24
$-3.5M
$-6.0M
Q3 24
$6.2M
$183.0M
Q2 24
$1.6M
$8.6M
Q1 24
$10.3M
$2.8M
Free Cash Flow
HCAT
HCAT
PRM
PRM
Q4 25
$9.6M
$11.6M
Q3 25
$-719.0K
$193.6M
Q2 25
$-9.2M
$-15.6M
Q1 25
$-390.0K
$18.9M
Q4 24
$-3.9M
$-12.4M
Q3 24
$5.5M
$179.1M
Q2 24
$1.3M
$5.0M
Q1 24
$10.1M
$1.2M
FCF Margin
HCAT
HCAT
PRM
PRM
Q4 25
12.9%
11.3%
Q3 25
-0.9%
61.4%
Q2 25
-11.4%
-9.6%
Q1 25
-0.5%
26.3%
Q4 24
-4.9%
-14.4%
Q3 24
7.2%
62.1%
Q2 24
1.7%
3.9%
Q1 24
13.5%
2.1%
Capex Intensity
HCAT
HCAT
PRM
PRM
Q4 25
0.4%
6.8%
Q3 25
0.3%
1.6%
Q2 25
0.3%
7.8%
Q1 25
0.8%
6.7%
Q4 24
0.5%
7.5%
Q3 24
0.9%
1.3%
Q2 24
0.4%
2.9%
Q1 24
0.3%
2.6%
Cash Conversion
HCAT
HCAT
PRM
PRM
Q4 25
Q3 25
Q2 25
Q1 25
0.42×
Q4 24
-0.04×
Q3 24
Q2 24
0.40×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

PRM
PRM

Products$87.7M85%
Service And Other$14.8M14%

Related Comparisons